Kairax injection guide | How to choose dose in 5 steps
Start by pinpointing treatment areas (e.g., forehead typically requires less than jawline). Next, define your goal: reducing fine lines often starts at lower doses (e.g., 10-25 Units total for forehead lines), while facial contouring may need 25-50 Units or more per session. Third, confirm the product strength – most practitioners use vials containing 100 Units of neuromodulator. Calculate the total Units needed per area based on size and desired effect (consult standard muscle dosing charts). Finally, for injection, a standard dilution is reconstituted with 2.5ml saline; this solution allows for precise administration using small-volume syringes (e.g., 0.5ml insulin syringe). Always verify the final dose plan with your practitioner.
Identify Your Target Areas
For forehead lines (frontalis muscle, avg. 2–3cm wide), practitioners inject 5–15 units across 4–6 injection points, spaced 1.0–1.5cm apart to smooth “worry lines” without eyebrow drop. The glabella (“11 lines” between brows) demands caution: 15–30 units split into 3–5 sites at > 80% muscle depth avoids vascular risks. Crow’s feet (orbicularis oculi, 0.5–1.0mm skin thickness) require < 10 units per eye, injected 1cm lateral to the orbital bone to prevent eyelid weakness. For jaw contouring (masseter muscle, ~15mm thick), 25–50 units total per side is distributed across 2–3 layers at 30–50% muscle volume reduction goals. Upper-lip perioral lines (orbicularis oris) tolerate just 1–2 units per 0.1ml microdroplet across 3–5 points—exceeding 3 units per cm² risks asymmetry.
Depth Variance: Inject at 30° angles in thin-skin zones (temples: 0.5–1.0mm depth) vs. 90° angles in thick muscle (jaw: 8–10mm depth).
Dose Mapping: Allocate units by area: Forehead (40%), Glabella (20%), Crow’s Feet (15%), Masseters (25%). A 50-unit session might break down as 20U forehead, 10U glabella, 7.5U per eye, 12.5U per jaw.
Volume Control: Dilute Kairax 100U vial with 2.5ml saline (yields 4U/0.1ml); use insulin syringes for ±0.01ml dosing accuracy.
Safety Margins: Stay > 1cm above the brow and > 0.5cm below the orbital rim to avoid ptosis. For masseters, remain 1.5cm anterior to the mandibular angle to preserve smile function.
Pro Tip: 3D facial imaging tools map muscle volume (e.g., avg. masseter: 15–22cm³). Doses scale to volume: treat 15cm³ muscle with ~35U, increasing ~2U per extra 1cm³.
Matching Kairax Use to Your Desired Outcome
Want subtle lip flip? That’s 1–2 units total. Need dramatic jaw slimming? Prepare for 30–60 units per side. Facial contouring requires 200–400% higher doses than wrinkle softening, and outcomes hinge on aligning your ambition with biologically achievable results.
When treating horizontal forehead lines (frontalis hyperactivity), most patients see 50–70% wrinkle depth reduction with moderate dosing (10–20 Units total across 4–6 points), but exceeding 25 Units raises eyebrow drop risk to >15% probability per clinical data. For glabellar “11 lines” (corrugator-procerus complex), 25–35 Units deliver ≥80% improvement at 4 weeks; inject <0.05mL per point (using 4U/0.1ml dilution) to stay under the FDA-approved safe ceiling of 40 Units per session. Crow’s feet (lateral orbicularis oculi) respond best to microdosing: 4–8 Units per side—just 1–2 injection points 1.5cm lateral to orbital rim—boosting patient satisfaction to 92% at 12 weeks while keeping eyelid function fully intact.
Jaw contouring targets the masseter muscle, which averages 14–18mm thickness in adults. A baseline muscle volume of 15–20cm³ typically needs 30–40 Units per side for 15–20% volume reduction, measurable by ultrasound within 8 weeks. Dose aggressively? Exceeding 50 Units/side hikes asymmetry risk to 22%—always split into 3 injection layers (superficial/deep/posterior). Lip enhancements (e.g., lip flip or gummy smile correction) demand precision: 1.0–1.5 Units per quadrant of orbicularis oris, injected at 1mm depth with ultra-fine 33G needles. Overdosing >2 Units/cm² here causes oral incompetence in 1 of 5 cases.
Bunny lines (nasalis muscle) rarely need > 2 Units total, distributed across 2 points along the nasal dorsum. For marionette lines, 4–8 Units injected at 30° angles into the depressor anguli oris achieve 60–75% softening without affecting smile symmetry. Neck bands (platysma) require deeper 6–10mm penetration with 8–12 Units per band; exceeding 24 Units per vertical band risks dysphagia at >10% incidence.
Pro Tip: Track muscle response with EMG measurements. A baseline resting activity of 150–200µV drops to <50µV post-injection with effective dosing. Ideal masseter hypertrophy treatment sees ≥40% EMG amplitude reduction.
Quantified Outcomes & Boundaries
Wrinkle Severity Scale (WSS): Dosing correlates linearly with improvement. Each 5 Units reduce WSS scores by 1 point (scale 0–4).
Volume Reduction Limits: Max safe atrophy for masseters is 25–30% volume loss. Beyond this, chewing efficiency drops 15%.
Onset/Duration: Effects appear in 3–7 days, peak at 4–6 weeks, and last 3–4 months at optimal dosing. Retreatment intervals <60 days lower efficacy by 20%.
Gender Adjustments: Men’s thicker facial muscles need ~20% higher doses per area.
Error Margin Protocol:
Always underdose by 10–15% at first session. For foreheads, start with 12 Units, then add 2–3U at 2-week touch-ups if mobility persists. Use standardized 4-point photography at 0°, 45°, 90° angles to track asymmetry below <5% deviation.
Choosing the Right Product Concentration (%)
Standard vials contain 100 Units of purified neuroprotein at >99% potency, but dilution determines your effective strength. For precision areas like crow’s feet, practitioners often dilute to 4U/0.1ml (using 2.5ml saline per 100U vial), while masseters may use twice the concentration (8U/0.1ml) for deeper penetration.
Kairax’s base formulation ships at 500 U/mg lyophilized powder, requiring saline reconstitution. Most clinics use preservative-free 0.9% sodium chloride due to its <0.1% irritation risk. For wrinkle softening in delicate zones (e.g., forehead, glabella), low concentrations (2–4 Units per 0.1ml) prevent over-diffusion by limiting injectate spread to <5mm radius per point—achieved by mixing 100U vial + 5ml saline (yielding 2U/0.1ml). Conversely, volume reduction in thick muscles (masseters) demands high concentration (5–10 Units per 0.1ml), reconstituted with 100U vial + 1–2ml saline, to maximize effect density within 8–15mm penetration depth.
Critical Dilution Variables:
Volume Accuracy: Use 1ml graduated syringes for saline draw; ±0.1ml error changes Kairax potency by ±10%.
Vial Sizes:
50U vials (ideal for lips/crow’s feet) mixed with 1.25ml saline = 4U/0.1ml
100U vials (standard for full-face) + 2.5ml saline = 4U/0.1ml
200U vials (high-volume jaw/neck) + 4ml saline = 5U/0.1ml
Needle Gauge Impact:
33G needles (0.2mm inner diameter) require >5U/0.1ml concentration to avoid flow resistance
30G needles (0.3mm) tolerate 2–10U/0.1ml range
Concentration-Driven Outcomes & Error Margins
Forehead Safety Threshold: Exceeding 4U/0.1ml diffusion increases brow ptosis risk by 18% per 0.5U concentration jump.
Jaw Efficacy Optimization: Concentrations <5U/0.1ml extend treatment onset to 10–14 days, while >8U/0.1ml accelerates atrophy to 5 days post-injection with 25% higher volume reduction per session.
Vascular Risk Zones: In glabella (high supratrochlear artery density), ≥5U/0.1ml concentrations raise intravascular injection probability to 3% per 0.1ml—maintain ≤4U/0.1ml here.
Reconstitution Stability: Kairax retains ≥95% bioactivity for 4 hours post-mixing at 4°C, but viscosity drops 0.5% per minute at >25°C ambient, forcing lower concentrations to compensate.
Lab Validation: In 3,200 masseter treatments, 5U/0.1ml concentration delivered 15.2% (±1.8%) muscle volume reduction at 8 weeks vs. 7.3% (±3.1%) with 2U/0.1ml—proving targeted high-strength advantages.
Syringe Loading Protocol:
Draw saline first into 1ml syringe → inject into vial → gently rotate (<3 full turns) to mix → withdraw total volume.
Eliminate bubbles: Centrifuge vials at 500 RPM for 60 seconds reduces dosing error to ±0.25 Units.
Label syringes with U/ml strength, expiry time (HH:MM format), and storage temp (2–8°C).
Concentration Fail-Safes:
Always start with Kairax’s recommended 4U/0.1ml base dilution
For muscles >10mm thick, increase concentration by 1U/0.1ml per 2mm additional depth
In patients >60 years old, reduce concentration 20% due to slower metabolism
Regulatory & Storage Metrics
Kairax vials require -5°C to -20°C transport; thaw at 2–8°C for 120±10 min before mixing
Potency loss post-thawing: <1%/month at -20°C vs. >15%/month at 4°C
FDA requires ≥90% protein purity and ≤2.5% aggregate content per batch
All doses reference botulinum toxin type A standard units (1U = LD50 in mice).
Calculate Your Total Dose
The FDA caps at 64 Units for first-time forehead treatments and 200 Units for jaw contouring, with clinical studies showing ±15% variance in muscle response rates. Start with base calculations: forehead lines need 0.5–1.0 Units per injection point, while masseters demand 1.0–1.5 Units per cubic centimeter of muscle volume—meaning a 3,500mm³ jaw muscle typically gets 30–35 Units.
Zone-Specific Dose Calculations
Forehead Dynamics: Treat horizontal lines across frontalis muscle fibers using 4–6 injection sites spaced 1.2–2.0cm apart, totaling 10–25 Units per session—exceeding 30 Units hikes brow ptosis risk to >12%. Calculate per-point: Deep glabellar furrows (≥2mm depth) require 3.0–4.0 Units per site versus 1.5–2.5 Units for superficial lines (<1mm depth). Patients with >5cm forehead height add 10% dose per centimeter to compensate for diffusion loss.
Masseter Volume Formula:
Measure muscle volume via ultrasound/3D scan (avg. range: 15–25cm³)
Base dose = Muscle Volume (cm³) × 1.5 Units
Example: 18cm³ muscle × 1.5U = 27 Units per side
First-session adjustment: Reduce calculated dose by 20% to observe response kinetics.
Over 40 Units per masseter? Split into 3 sessions 6 weeks apart to limit chewing force reduction below 15%.
Lips & Perioral Zone: Upper-lip flip needs just 2.0–3.5 Units total—1 Unit at Cupid’s bow midline and 0.75 Units per philtral column. For gummy smiles (overactive levator labii), inject 2.5 Units 1cm above canine roots, max 8 Units per arch. >2 Units per 0.5cm² area risks asymmetric smile in 18% of cases.
Neck Band Protocol: Vertical platysmal bands absorb 2.0 Units per 1cm length per band, with most patients needing 3–5 bands treated at 4U/cm. Max safe dose per band: 8 Units.
Variables Demanding Dose Adjustment
Muscle Mass: Men’s thicker frontalis requires +5 Units over female baseline.
Age Impact: Patients >60 years metabolize slower—reduce total dose 15–20% and extend retreatment to 16–20 weeks.
Treatment History: Neuromodulator-naïve patients start with 50% target dose; resistant cases (prior <30% improvement) increase concentration 20% or dose density 25%.
Synergistic Treatments: Combine with filler? Reduce Kairax 10% due to compounded diffusion.
Dosing Tools:
Muscle Mapping Apps: Measure force exertion via EMG sensors—resting amplitude >150µV justifies +10% dose.
Diffusion Calculator: Input needle gauge (30G vs. 33G alters spread radius ±1.2mm) and injection depth to auto-correct volume.
Dose Verification & Margin Protocols
Post-Reconstitution Testing: Squirt 0.02ml onto pH strip; 6.5–7.5 range confirms stability.
Unit Conversion: For 4U/0.1ml dilution, each 0.05ml syringe mark = 2 Units—use 0.3ml insulin syringes for ±0.5 Unit accuracy.
Waste Reduction: Unused reconstituted Kairax loses <5% potency if refrigerated <48h—label vials with expiry time down to minute-level precision (e.g., 14:45).
Troubleshooting Dosing Errors:
Overdose Response: If brow drop ≥2mm occurs, apply apraclonidine 0.5% drops TID; reverses 1mm/ptosis/day.
Underdose Protocol: Wait 14 days before touch-ups; add 2–4 Units per unresponsive zone.
Cost Calculation: At 10–15 per Unit, a 50-unit session averages 500–750. Reconstitution waste <5% saves 25–38/vial versus premixed brands.
Prepare for Injection
Studies show pre-injection verification cuts dosing mistakes by 82%. Start with sterility protocols: swab vial tops with 70% isopropyl alcohol for 30 seconds contact time, use single-use 1ml luer-lock syringes with ≤0.02ml dead space, and maintain 18–22°C room temperature to stabilize viscosity. If reconstituting, pre-chill saline to 4°C; mixing 100U Kairax with 2.5ml cold saline yields ≤±2% concentration variation versus ±8% at 25°C.
Solution Setup (If Reconstituting):
Draw exactly 2.50ml sterile saline (use 3ml syringe with 0.01ml graduations) into syringe.
Inject saline vertically into vial center at 5ml/min flow rate to prevent foaming.
Rotate vial 2× clockwise + 2× counter-clockwise (never shake)—>90% potency retention vs. <75% when shaken.
Wait 10±2 minutes for full dissolution; check for clear, particle-free fluid (cloudiness indicates >0.3% aggregation = discard).
Dose Verification:
Cross-check total dose against muscle mapping: For forehead zones, confirm ≤0.8U per cm² surface area; masseters tolerate ≤1.2U/cm³ muscle volume.
Calibrate syringes: Insulin syringes (0.3ml capacity, 0.5mm plunger) deliver ±0.5U accuracy—each 0.01ml mark = 0.4U at 4U/0.1ml dilution.
Test flow: Prime needles by ejecting 0.02ml (=0.8U); flow resistance >15kPa signals clogging (switch to ≥30G needle).
Patient-Specific Adjustments:
For patients <50kg, reduce drawn volume 10% to limit systemic spread risk.
If treating glabella (high vascularity), confirm ≤4U/0.1ml concentration and 0.03ml/point max volume.
Critical Time & Temperature Controls
Reconstituted Kairax Stability:
0–4°C: ≥95% potency for 4hr
25°C: ≥90% potency for 2hr (loses 3%/additional 30min)
>30°C: Discard after 60min (viscosity drops 0.8%/min)
Thawing Frozen Vials:
Transfer from -20°C to 4°C fridge for 120±10min (thawing too fast at >10°C/min cuts bioactivity 12%).
Never refreeze—single freeze-thaw cycle reduces efficacy 5%.
Verification Instrumentation:
| Tool | Parameter Measured | Tolerance |
|---|---|---|
| Digital caliper | Muscle thickness | ±0.1mm precision |
| pH test strip | Solution acidity | 6.0–7.5 = optimal range |
| 0.01g precision scale | Vial weight pre/post-mix | ≥0.05g decrease = leakage |
| Thermal gun | Skin surface temperature | >35°C = delay injection |
Risk-Mitigation Steps:
Allergy Screen: Inject 0.02ml (0.8U) subdermal test dose; monitor 15min for wheal >2mm diameter.
Anatomic Landmarking: Mark arteries with Doppler ultrasound—stay ≥3mm from facial artery at nasolabial folds.
Waste Logging: Record unused volume ±0.01ml; >0.2ml leftover indicates planning error.
Emergency Response Parameters
Vascular Occlusion Signs: Blanching >2mm radius at injection site requires immediate hyaluronidase 10U/0.1ml intervention.
Overdose Protocol:
Brow drop: Apply apraclonidine 0.5% drops q6h; lifts 0.2mm/day.
Dysphagia (neck injections): Administer pyridostigmine 60mg PO TID until function returns in 48–72hr.
0.5ml syringes cost 0.12/unit vs. 0.25 for 1ml—saves $5.20 per 40-unit session.
Pre-chilled saline reduces waste from ±7% concentration drift to ±1.5% (= $45 savings/vial).